T 0139/16 (Anti-HER2 antibody formulations / HOFFMANN-LA ROCHE) of 07.02.2019
- European Case Law Identifier
- ECLI:EP:BA:2019:T013916.20190207
- Date of decision
- 7 February 2019
- Case number
- T 0139/16
- Online on
- 14 March 2019
- Petition for review of
- -
- Application number
- 10737891.1
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- SUBCUTANEOUS ANTI-HER2 ANTIBODY FORMULATION
- Applicant name
- F. Hoffmann-La Roche AG
- Opponent name
- HGF Limited
- Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 113(1)Rules of procedure of the Boards of Appeal Art 13(1)Rules of procedure of the Boards of Appeal Art 13(3)European Patent Convention Art 56European Patent Convention Art 54European Patent Convention Art 123(2)European Patent Convention Art 100(b)
- Keywords
- Inventive step - main request (yes)
Oral proceedings - held in absence of appellant
Admission of documents in first instance proceedings - proper exercise of discretion (yes)
Novelty - (yes)
Sufficiency of disclosure - (yes)
Amendments - added subject-matter (no) - Catchword
- -
- Cited cases
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division with the order to maintain the patent on the basis of the main request filed with letter dated 7 January 2019 and a description to be adapted.